KOE:298380

ABL Bio Inc. · KOE · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:19 UTC

Last close

n/aKRW

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-47.7%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-77.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

Price is the furthest below its sector's middle: 0.06 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.70x

0.87x

2.45x

2.51x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales2.70x
Its own average over 9 years, 29.37B.
Profit0.87x
Its own average over 10 years, -43.47B.
Free cash flow2.45x
Its own average over 10 years, -25.03B.
Debt2.51x
Its own average over 9 years, 22.07B.
Pricen/a
Its own average over 0 years. Market data

Sales is furthest from its own average, at 2.70 times.

Sales is 2.70 times its own 9-year average; Profit is 0.87 times its own 10-year average; Free cash flow is 2.45 times its own 10-year average; Debt is 2.51 times its own 9-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 9-year average2.70
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 10-year average0.87
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 10-year average2.45
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 9-year average2.51
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW